A U.S. Court of Appeals for the Federal Circuit panel on Tuesday confirmed that a number of biotechnology patents filed by Pacific Biosciences were invalid, upholding findings reached in March 2020 by the U.S. District of Delaware’s final pre-pandemic jury, which found in favor of a British-based pharma company.

The patents at issue related to DNA sequencing technology, which Pacific Biosciences of California Inc. claimed that counsel for Oxford Nanopore Technologies had unfairly played up as relevant to the pandemic.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]